163 related articles for article (PubMed ID: 38448905)
1. Construction of a prognostic model for hepatocellular carcinoma patients receiving transarterial chemoembolization treatment based on the Tumor Burden Score.
Lin J; Li J; Kong Y; Yang J; Zhang Y; Zhu G; Yu Z; Xia J
BMC Cancer; 2024 Mar; 24(1):306. PubMed ID: 38448905
[TBL] [Abstract][Full Text] [Related]
2. Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Ho SY; Liu PH; Hsu CY; Ko CC; Huang YH; Su CW; Lee RC; Tsai PH; Hou MC; Huo TI
J Gastroenterol Hepatol; 2021 Nov; 36(11):3196-3203. PubMed ID: 34159651
[TBL] [Abstract][Full Text] [Related]
3. A prognostic score model for predicting the survival benefits of patients undergoing sorafenib plus transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion.
Li JR; Wu MJ; Wang T; Tian M; Zhou G; Liu QX; Xiang XH; Zhang YQ
Abdom Radiol (NY); 2021 May; 46(5):1967-1976. PubMed ID: 33386450
[TBL] [Abstract][Full Text] [Related]
4. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
5. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
6. Surgical resection versus transarterial chemoembolization for patients with hepatocellular carcinoma beyond Milan criteria: prognostic role of tumor burden score.
Ho SY; Liu PH; Hsu CY; Huang YH; Lei HJ; Liao JI; Su CW; Hou MC; Huo TI
Sci Rep; 2023 Aug; 13(1):13871. PubMed ID: 37620558
[TBL] [Abstract][Full Text] [Related]
7. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Jia KF; Wang H; Yu CL; Yin WL; Zhang XD; Wang F; Sun C; Shen W
Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):490-497. PubMed ID: 35260337
[TBL] [Abstract][Full Text] [Related]
8. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study.
Wang Q; Xia D; Bai W; Wang E; Sun J; Huang M; Mu W; Yin G; Li H; Zhao H; Li J; Zhang C; Zhu X; Wu J; Li J; Gong W; Li Z; Lin Z; Pan X; Shi H; Shao G; Liu J; Yang S; Zheng Y; Xu J; Song J; Wang W; Wang Z; Zhang Y; Ding R; Zhang H; Yu H; Zheng L; Gu W; You N; Wang G; Zhang S; Feng L; Liu L; Zhang P; Li X; Chen J; Xu T; Zhou W; Zeng H; Zhang Y; Huang W; Jiang W; Zhang W; Shao W; Li L; Niu J; Yuan J; Li X; Lv Y; Li K; Yin Z; Xia J; Fan D; Han G;
J Hepatol; 2019 May; 70(5):893-903. PubMed ID: 30660709
[TBL] [Abstract][Full Text] [Related]
9. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
10. Postsurgical treatment with adjuvant transarterial chemoembolization in patients with hepatitis B-related hepatocellular carcinoma: A strobe-compliant article.
Hu H; Liu R; Long XR; Han XK; Fan J; Yan ZP; Wang JH
Medicine (Baltimore); 2016 Dec; 95(52):e5517. PubMed ID: 28033246
[TBL] [Abstract][Full Text] [Related]
11. A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava.
Chu HH; Chun SY; Kim JH; Kim PH; Il Gwon D; Ko HK; Kim N
Eur Radiol; 2021 Jun; 31(6):4232-4242. PubMed ID: 33241523
[TBL] [Abstract][Full Text] [Related]
12. The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.
Zhang Y; Miao H; Xie W; Jiang S; Song Z; Huang G; Fan W; Wang Y; Li J; Chen Y
Eur Radiol; 2021 Jan; 31(1):232-243. PubMed ID: 32728770
[TBL] [Abstract][Full Text] [Related]
13. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
Niu XK; He XF
World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients.
Park KH; Kim JH; Choe WH; Kwon SY; Yoo BC; Hwang JH; Park SW; Kim YJ; Park HS; Yu MH; Jeon HJ
Korean J Gastroenterol; 2020 Mar; 75(3):147-156. PubMed ID: 32209803
[TBL] [Abstract][Full Text] [Related]
16. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
17. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
[TBL] [Abstract][Full Text] [Related]
18. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.
Liu S; Li H; Guo L; Zhang B; Zhou B; Zhang W; Zhou J; Fan J; Ye Q
Oncologist; 2019 Apr; 24(4):513-520. PubMed ID: 30552155
[TBL] [Abstract][Full Text] [Related]
19. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Survival Factors of Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Rohan T; Uher M; Matkulčík P; Zavadil J; Ostřížková L; Kiss I; Andrašina T; Válek V
Klin Onkol; 2020; 33(3):214-219. PubMed ID: 32683878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
